This study will measure plasma concentrations of bivalirudin in pediatric patients undergoing cardiac catheterization, cardiac surgical procedures utilizing cardiopulmonary bypass (CPB), or extracorporeal support with ECMO, ventricular support devices (VAD) or lung-assist devices (LAD). The aim is to understand the pharmacokinetics of bivalirudin in these settings.
pediatric patient (age less than 18 years)
weight > 3kg
scheduled to undergo 1) cardiac catheterization, 2)cardiac surgical procedure utilizing CPB, and/or 3) the institution of extracorporeal support
must already require the administration of bivalirudin as part of their treatment plan
Age equal to or greater than 18 years,
weight less than 3kg
end-stage renal failure requiring renal replacement therapy.
September 5, 2021
Primary Contact Information
Zaleski L Zaleski, MD
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: